Iovance Biotherapeutics, Inc. (IOVA)
| Market Cap | 1.62B +46.7% |
| Revenue (ttm) | 285.61M +34.3% |
| Net Income | -353.86M |
| EPS | -0.93 |
| Shares Out | 446.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,688,669 |
| Open | 3.520 |
| Previous Close | 3.550 |
| Day's Range | 3.380 - 3.620 |
| 52-Week Range | 1.639 - 5.630 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 8.78 (+142.54%) |
| Earnings Date | May 7, 2026 |
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients w... [Read more]
Financial Performance
In 2025, Iovance Biotherapeutics's revenue was $263.50 million, an increase of 60.60% compared to the previous year's $164.07 million. Losses were -$390.98 million, 5.05% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price target is $8.78, which is an increase of 142.54% from the latest price.
News
Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan
Chardan lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $14 from $16 and keeps a Buy rating on the shares. The firm is adjusting its model to reflect
Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)
Reports Q1 revenue $71.43M, consensus $75.66M. Frederick Vogt, interim President and Chief Executive Officer of Iovance, stated, “We are accelerating the adoption and commercial expansion for Amtagvi ...
Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M
Sees Q2 Amtagvi revenue $79M-$81M.
Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M
08:11 EDT Iovance Biotherapeutics (IOVA) sees FY26 revenue $350M-$370M, consensus $359.68M
Iovance Biotherapeutics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 45% year-over-year, driven by strong AMTAGVI demand and expanding adoption. Guidance for Q2 and full-year 2026 remains robust, with operational efficiencies expected to improve margins and extend the cash runway into 2028.
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
1Q26 Total Revenue of ~$71M Delivers ~ 45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial...
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliver...
Replimune CRL positive for Iovance in near-term, says Chardan
Chardan analyst Geulah Livshits keeps a Buy rating on Iovance Biotherapeutics (IOVA) with a $16 price target after Replimune (REPL) received a second complete response letter from the FDA for
Unusually active option classes on open April 10th
Unusual total active option classes on open include: Iovance Biotherapeutics (IOVA), Eos Energy (EOSE), Klarna Group PLC (KLAR), Astera Labs Inc (ALAB), Palantir Technologies (PLTR), AMC Entertainment...
Iovance Biotherapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Three strategic pillars—commercial growth, pipeline expansion, and operational excellence—are driving strong momentum, with Amtagvi showing robust real-world efficacy and margin improvements. Pipeline advances in lung cancer, sarcoma, and next-gen TILs, plus global expansion, position the business for significant growth in 2026 and beyond.
Iovance Biotherapeutics call volume above normal and directionally bullish
Bullish option flow detected in Iovance Biotherapeutics (IOVA) with 27,841 calls trading, 5x expected, and implied vol increasing over 8 points to 112.30%. 3/6 weekly 4.5 calls and Jan-27 3.5
Iovance Biotherapeutics price target raised to $4 from $2 at UBS
UBS analyst David Dai raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $4 from $2 and keeps a Neutral rating on the shares. Fundamentals improved in Q4, but
Iovance Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Strong Q4 and full-year financials were driven by AMTAGVI adoption and operational improvements, with a focus on expanding treatment center networks and advancing a robust pipeline. Key clinical milestones are expected in lung cancer and sarcoma, with next-generation TIL therapies in development.
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Iovance Biotherapeutics price target raised to $4 from $3 at Baird
Baird raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $4 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results
Iovance Biotherapeutics price target raised to $11 from $10 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $11 from $10 and keeps an Overweight rating on the shares. The company’s Q4 products beats
Iovance upgraded to Outperform from Market Perform at Citizens
Citizens upgraded Iovance Biotherapeutics (IOVA) to Outperform from Market Perform with a $5 price target The company reported 30% sequential revenue growth in Q4 and highlighted progress across its n...
Iovance Biotherapeutics price target lowered to $16 from $17 at Chardan
Chardan analyst Geulah Livshits lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $16 from $17 and keeps a Buy rating on the shares. The company reported a gross
Unusually active option classes on open February 24th
Unusual total active option classes on open include: Iovance Biotherapeutics (IOVA), Global X Uranium (URA), Teva (TEVA), Upwork (UPWK), Home Depot (HD), Constellation Energy (CEG), Advanced Micro Dev...
Iovance Biotherapeutics Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw 61% revenue growth, record gross margins, and strong AMTAGVI adoption. Pipeline advances include FDA Fast Track for lifileucel in lung cancer and positive sarcoma data, with global expansion and further revenue growth expected in 2026.
Iovance Biotherapeutics reports Q4 EPS (18c), consensus (18c)
Reports Q4 revenue $86.711M, consensus $81.01M. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “Iovance delivered approximately 30 percent quarterly rev...
Iovance Biotherapeutics announces results from trial for TIL cell therapy
Iovance Biotherapeutics (IOVA) announced positive early data from a pilot clinical trial led by Memorial Sloan Kettering Cancer Center, MSKCC, and supported by Iovance of lifileucel in patients with a...
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona...
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE N...